Background Positivity for rheumatoid factor (RF), anti–cyclic citrullinated peptide antibodies (anti-CCP) and high gamma globulin levels are predictive of better response to rituximab forrheumatoid arthritis (RA) . Magnusson et al. showed a better response to RTX in patients with positive initial EBV load .
Objectives To study the influence of several factors (FR, Anti-CCP, serum gamma globulin level, EBV load) on response to RTX.
Methods Patients treated by RTX for active RA in the rheumatology department of the university hospital of Clermont-Ferrand (France) between April 2006 and May 2011 were prospectively included. RF, anti-CCP, gamma globulin level and EBV load were measured before the first RTX cycle. Clinical response were analysed 6 months after RTX according to the criteria the European league against rheumatism (EULAR). Univariate and multivariate analyses were performed to identify factors associated with response to RTX at 6 months.
Results Sixty-four patients (51 women (79.7%), mean age =61.2 years) were included. Mean disease duration was 16.4 years and 46 patients (71.8%) had already received one or more anti-TNF treatments. At 6 months, 46 patients (71.8%) had moderate-to-good response to RTX. Thirty-seven patients, of whom 6 were positive, had EBV-load measure before RTX. After 6 months, all were negative. Positivity for RF (odds ratio 0,53 [95% confidence interval O,1-2,8]), or positive initial EBV load (odds ratio 0,2 [95% confidence interval 0,03 – 1,3])were not associated with good-to-moderate response. Positivity for anti-CCP was associated with good-to-moderate response (odds ration 4,3 [95% confidence interval 1,2 – 15,7]). High level of gammaglobulin (>12g/L) was correlated with non-response to RTX (odds ratio 0,05 [95% confidence interval 0,03-0,66]).
Conclusions In contrast with precedent studies, high level of gamma globulins was predictive of worth response to RTX and only anti-CCP antibodies were correlated to a better response.
Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63:933-8.
Magnusson M, Brisslert, Zendjanchi K, Lindh M, Bokarewa MI. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford). 2010;49:1911-9.
Disclosure of Interest None Declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.